简介:PURPOSE:ResistancetotemozolomidechemotherapyispartlymediatedbyO^6-methylguanine-DNAmethlytransferase(MGMT).ProtractedtreatmentwithtemozolomidepotentiallyovercomesMGMTresistanceandimprovesoutcome.WeconductedaphaseIIstudyofprotracteddailytemozolomideinadultswithlow-gradegliomas.EXPERIMENTALDESIGN:PatientswithnewlydiagnosedoligodendrogliomaoroligoastrocytomawithaMIB-1indexof〉5%orrecurrentlow-gradegliomasreceivedtemozolomide(75mg/m^2/dayin11-weekcyclesof7weekson/4weeksoff).Treatmentcontinuedforatotalofsixcyclesoruntiltumorprogressionorunacceptabletoxicity.Primaryendpointwasbestoverallresponserate;secondaryendpointswereprogression-freesurvival,overallsurvival,andtoxicity.
简介:BACKGROUND:In2004,arandomisedphaseⅢtrialbytheEuropeanOrganisationforResearchandTreatmentofCancer(EORTC)andNationalCancerInstituteofCanadaClinicalTrialsGroup(NCIC)reportedimprovedmedianand2-yearsurvivalforpatientswithglioblastomatreatedwithconcomitantandadjuvanttemozolomideandradiotherapy.We'reportthefinalresultswithamedianfollow-upofmorethan5years.METHODS:Adultpatientswithnewlydiagnosedglioblastomawererandomlyassignedtoreceiveeitherstandardradiotherapyoridenticalradiotherapywithconcomitanttemozolomidefollowedbyuptosixcyclesofadjuvanttemozolomide.